MedPath

A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

Phase 4
Withdrawn
Conditions
Allergic Rhinitis
Interventions
Drug: placebo, isotonic ciclesonide, hypotonic ciclesonide
Registration Number
NCT00793858
Lead Sponsor
University of Chicago
Brief Summary

The purpose of this study is to measure the amount of a nasal steroid spray (ciclesonide) absorbed by the tissue in the nose 2 hours after having this study drug sprayed in the nose

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  1. Males and females 18 years of age or older.
  2. History of perennial allergic rhinitis for at least 1 year prior to screening.
  3. Positive skin test to perennial allergen.
Exclusion Criteria
  1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
  2. Pregnant or lactating women.
  3. Upper respiratory infection within 14 days of study start.
  4. Active asthma requiring treatment with inhaled or systemic steroids.
  5. Use of any form of nasal spray during the previous month.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
4placebo, isotonic ciclesonide, hypotonic ciclesonideisotonic ciclesonide in both right and left nostrils
1placebo, isotonic ciclesonide, hypotonic ciclesonideplacebo in left nostril, isotonic ciclesonide in right
2placebo, isotonic ciclesonide, hypotonic ciclesonidehypotonic ciclesonide in left nostril, placebo in right
3placebo, isotonic ciclesonide, hypotonic ciclesonidehypotonic ciclesonide in right and left nostrils
6placebo, isotonic ciclesonide, hypotonic ciclesonideplacebo in both right and left nostrils
5placebo, isotonic ciclesonide, hypotonic ciclesonideisotonic ciclesonide in left nostril and hypotonic ciclesonide in right
Primary Outcome Measures
NameTimeMethod
levels of ciclesonide in biopsy tissue2 hours post study drug administration
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Chicago Medical Center

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath